Immune Repertoire Sequencing
To increase the efficiency and cost-effectiveness of rational medication development, Immune Repertoire Sequencing is widely used in biomarker discovery. For instance, through its Biomarker and Diagnostic unit in Canada, the Center for Commercialization of Cancer Immunotherapy (C3i) began providing T cell receptor-beta sequencing services in November 2017. The market for immune repertoire sequencing is anticipated to develop as a result of rising demand for customised medicine, which analyses a person's genetic profile to inform decisions about the diagnosis, prevention, and treatment of illnesses.
Watch Video - https://lumen5.com/user/poojasalve/immune-repertoire-se-jpdqn/
